We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The renowned genetic testing company reported adjusted earnings per share (EPS) of 14 cents in the last reported quarter, topping the Zacks Consensus Estimate by 27.27%. GeneDx surpassed estimates in each of the trailing four quarters, the average surprise being 164.21%.
Q1 Estimates for WGS
The Zacks Consensus Estimate for GeneDx’s first-quarter 2026 revenues is pegged at $110.5 million. This suggests a 26.9% rise from the year-ago reported figure.
The Zacks Consensus Estimate for its first-quarter 2026 loss per share stands at 6 cents, compared to the year-ago quarter’s EPS of 28 cents.
Estimate Revision Trend Ahead of GeneDx’s Q1 Earnings
Estimates for GeneDx’s first-quarter loss have remained constant at 6 cents per share in the past 60 days.
Here’s a brief overview of the company’s progress ahead of this announcement.
Factors at Play
Building on a strong finish to 2025, GeneDx is likely to have extended the exome and genome momentum in the first quarter. The company continues to emphasize balancing high growth and profitability to address the large unmet needs in genetic diagnosis. Throughout last year, exome and genome test volumes steadily accelerated, and the company also saw geneticists increasingly shift toward whole genome, signaling a need to generate deeper data for their hardest-to-diagnose patients.
The FDA granted breakthrough device designation to the ExomeDx and GenomeDx tests, both powered by the GeneDx Infinity — the largest and most diverse rare-disease dataset composed of more than 2.5 million rare genetic tests, more than 1 million exomes and genomes and above 8 million phenotypic data points. All these factors are expected to have positively supported the company’s top-line performance. Meanwhile, reimbursement variations for exome and genome have likely stayed in the first quarter due to mix dynamics in the outpatient setting.
The company is also likely to have continued to benefit from multiple growth levers, including driving higher utilization among existing clinicians and introducing its tests to new markets. The foundational markets — geneticists and pediatric specialists — accounted for the most growth in the fourth quarter. GeneDx’s first-mover position, focused sales strategy, strong product portfolio, geneticist endorsements and experienced market access teams across the four newer U.S. markets — prenatal, NICU, adult specialists and general pediatricians — are likely to have provided a solid boost to the quarter’s revenues.
We also expect the company’s gross margin to have remained strong in the first quarter of 2026, reflecting its ability to lower the cost curve with scale over time.
Earnings Whispers for WGS Stock
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:
WGS’ Earnings ESP: GeneDx has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Agenus (AGEN - Free Report) has an Earnings ESP of +7.69% and a Zacks Rank #1. The company is expected to release first-quarter 2026 results soon.
In the trailing four quarters, AGEN delivered an average surprise of 31.42%. The Zacks Consensus Estimate implies that the company’s first-quarter EPS will increase 289.3% from the year-ago quarter’s figure.
Encompass Health (EHC - Free Report) has an Earnings ESP of +0.17% and a Zacks Rank #2. The company is slated to release first-quarter 2026 results on April 30.
EHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 12.09%. The Zacks Consensus Estimate suggests that EHC’s first-quarter EPS will rise 10.2% from the year-ago reported figure.
The Ensign Group (ENSG - Free Report) has an Earnings ESP of +1.12% and a Zacks Rank #2. The company is expected to release first-quarter 2026 results soon.
ENSG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.93%. The Zacks Consensus Estimate for the company’s first-quarter EPS calls for an increase of 17.8% from the year-ago quarter’s figure.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Will Robust Exome and Genome Revenues Lift GeneDx's Q1 Earnings?
Key Takeaways
GeneDx Holdings Corp. (WGS - Free Report) is slated to report its first-quarter 2026 results on May 4, after the market closes.
The renowned genetic testing company reported adjusted earnings per share (EPS) of 14 cents in the last reported quarter, topping the Zacks Consensus Estimate by 27.27%. GeneDx surpassed estimates in each of the trailing four quarters, the average surprise being 164.21%.
Q1 Estimates for WGS
The Zacks Consensus Estimate for GeneDx’s first-quarter 2026 revenues is pegged at $110.5 million. This suggests a 26.9% rise from the year-ago reported figure.
The Zacks Consensus Estimate for its first-quarter 2026 loss per share stands at 6 cents, compared to the year-ago quarter’s EPS of 28 cents.
Estimate Revision Trend Ahead of GeneDx’s Q1 Earnings
Estimates for GeneDx’s first-quarter loss have remained constant at 6 cents per share in the past 60 days.
Here’s a brief overview of the company’s progress ahead of this announcement.
Factors at Play
Building on a strong finish to 2025, GeneDx is likely to have extended the exome and genome momentum in the first quarter. The company continues to emphasize balancing high growth and profitability to address the large unmet needs in genetic diagnosis. Throughout last year, exome and genome test volumes steadily accelerated, and the company also saw geneticists increasingly shift toward whole genome, signaling a need to generate deeper data for their hardest-to-diagnose patients.
The FDA granted breakthrough device designation to the ExomeDx and GenomeDx tests, both powered by the GeneDx Infinity — the largest and most diverse rare-disease dataset composed of more than 2.5 million rare genetic tests, more than 1 million exomes and genomes and above 8 million phenotypic data points. All these factors are expected to have positively supported the company’s top-line performance. Meanwhile, reimbursement variations for exome and genome have likely stayed in the first quarter due to mix dynamics in the outpatient setting.
GeneDx Holdings Corp. Price and EPS Surprise
GeneDx Holdings Corp. price-eps-surprise | GeneDx Holdings Corp. Quote
The company is also likely to have continued to benefit from multiple growth levers, including driving higher utilization among existing clinicians and introducing its tests to new markets. The foundational markets — geneticists and pediatric specialists — accounted for the most growth in the fourth quarter. GeneDx’s first-mover position, focused sales strategy, strong product portfolio, geneticist endorsements and experienced market access teams across the four newer U.S. markets — prenatal, NICU, adult specialists and general pediatricians — are likely to have provided a solid boost to the quarter’s revenues.
We also expect the company’s gross margin to have remained strong in the first quarter of 2026, reflecting its ability to lower the cost curve with scale over time.
Earnings Whispers for WGS Stock
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:
WGS’ Earnings ESP: GeneDx has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
WGS’ Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Top MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Agenus (AGEN - Free Report) has an Earnings ESP of +7.69% and a Zacks Rank #1. The company is expected to release first-quarter 2026 results soon.
In the trailing four quarters, AGEN delivered an average surprise of 31.42%. The Zacks Consensus Estimate implies that the company’s first-quarter EPS will increase 289.3% from the year-ago quarter’s figure.
Encompass Health (EHC - Free Report) has an Earnings ESP of +0.17% and a Zacks Rank #2. The company is slated to release first-quarter 2026 results on April 30.
EHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 12.09%. The Zacks Consensus Estimate suggests that EHC’s first-quarter EPS will rise 10.2% from the year-ago reported figure.
The Ensign Group (ENSG - Free Report) has an Earnings ESP of +1.12% and a Zacks Rank #2. The company is expected to release first-quarter 2026 results soon.
ENSG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.93%. The Zacks Consensus Estimate for the company’s first-quarter EPS calls for an increase of 17.8% from the year-ago quarter’s figure.